Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics

Sandborn WJ, Colombel J-F, Schreiber S, Plevy SE, Pollack PF, Robinson AM, Chao J, Mulani P

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
20848500

DOI
10.1002/ibd.21328

Indexing Status
Subject indexing assigned by NLM

MeSH
Adalimumab; Adult; Anti-Inflammatory Agents /administration & dosage /economics; Antibodies, Monoclonal /administration & dosage /economics; Antibodies, Monoclonal, Humanized; Crohn Disease /drug therapy /economics; Dose-Response Relationship, Drug; Double-Blind Method; Economics, Pharmaceutical; Female; Humans; Long-Term Care; Male; Placebos; Treatment Outcome; Tumor Necrosis Factor-alpha /antagonists & inhibitors /immunology

AccessionNumber
22011000092

Date bibliographic record published
18/05/2011